Resonance surges on UK approval

Shares in Resonance Health jumped 53 per cent today after its FerriScan technology was recommended for use under a new set of medical guidelines in the UK.

The company’s shares lifted to 2.3 cents today on the positive news, up from 1.5 cents on Friday.

This followed an announcement at the 42^nd Academic Meeting of the UK Forum on Haemoglobin Disorders, where a new set of guidelines, UK Standards of Care for Thalassaemia, was launched commending the FerriScan technology.

“FerriScan has become the gold standard for measurement of liver iron concentration in haemoglobin disorders,” Resonance chief scientific officer Timothy St Pierre said.

“The UK standards of care further substantiate the position of FerriScan as the only method that offers the standardisation that is a prerequisite for reliable measurements on which to base patient treatment decisions.”

The technology was developed at the University of Western Australia by Professor St Pierre and has been used with 30,000 patients across 30 countries worldwide.

Today’s bounce comes after the company’s share price has trended lower during the past two years.

Resonance UK-based marketing director Melanie Baxter said recognition of FerriScan as the preferred technique was expected to assist with increasing clinician interest, as well as funding for the technology in the UK.

“We will now leverage the new UK standards of care in our global marketing efforts to increase the FerriScan use, raise awareness of the limitations of competitive products, empower patients to request optimum care and support the growth of our clinical network,” she said.